摘要
对中国缬草属植物进行了全面的分类整理,我国共有30种,4变种,2栽培种,并发现2新种(凤凰缬草、轮叶缬草),2个新栽培变种(红花中国缬草、白花中国缬草),均可作为缬草类药材的新资源植物。从形态、化学、DNA、细胞学角度对中国缬草及同属植物进行了种间及种内变异的研究,初步阐明了中国缬草种内变异的规律,为区分欧缬草与中国缬草并建立中国缬草新种提供了依据。对中国缬草进行了化学成分、镇静催眠作用以及发芽率等的比较研究,为生药资源开发提供了依据。
By the taxonomical study of Valeriana L. in China, we made it clear that there were 30 species, four varietas and two cultispecies in China. Among them ,two new species, two new cultispecies, i.e, Valeriana trifolium B. K. Huang et H. C. Zheng、 V. fenghuangensis B. K. Huang et H. C. Zheng, V. pseudofficinalis C. Y. Cheng et H. B. Chen 'Honghua' and V. pseudofficinalis C. Y. Cheng et H. B. Chen 'Baihua' were discovered, which could be regarded as new medicinal plants. We also fulfilled the studies on intraspecific and interspecific variations of V. pseudofficinalis and its sibling plant on the basis of morphology, cytology, chemistry and molecular genetics studies. The seed germinate rate, chemical components and sedative and hypnotic activities of V. pseudofficinalis were comparably studied. All studies could provide scientific basis for exploitation of resources of Valerian, spp. in China.
引文
1. Aibi DM, Bourguignon C, Taylor AG. Valerian use for sleep disturbances related to rheumatoid arthritis. Holist-Nurs-Pract. 2004, 18(3): 120-126.
2. Andreatini R, Sartori VA, Seabra ML, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002, 16(7): 650-654.
3. Arce S, Cerutti S, Olsina R, et al. Determination of metal content in valerian root phytopharmaceutical derivatives by atomic spectrometry. J AOAC Int. 2005, 88(1): 221-225.
4. Belaeva V A, Splivinsky V N, Chromosome numbers and taxonomy of some species of Baikai flora. Bot. Zurn. SSSr, 1975, 60(6): 864-872.
5. Bell, C. D. Preliminary phylogeny of Valerianaceae(Dipsacales) inferred from nuclear and chloroplast DNA sequence data. Mol. Phylogenet. Evol. 2004, 31(1), 340-350.
6. Bicchi C, Drigo S, Rubiolo P. Influence of fibre coating in headspace solid-phase microextraction-gas chromatographic analysis of aromatic and medicinal plants. J Chromatogr A. 2000, 892(1-2): 469-485.
7. Bicchi C. Bineilo A. Rubiolo P. Packed column SFC/UV versus HPLC/UV analysis of valerenic acids and valepotriates in extracts of Valeriana officinalis L. Phytochemical Analysis. 2000, 11(3): 179-183.
8. Bodesheim U. Holzl J. Isolation and receptor binding properties of alkaloids and ligans from Valeriana officinalis L. Pharmazie. 1997, 52(5): 386-391.
9. Borowitz RM., Gentill, b. Fiavonoid of Citrus-Ⅵ, the Structure of neohesperidose, tetrahedron. 1963, (19): 773-776.
10. Bos R, Hendriks H, Scheffer JJC, et al. Cytotoxic Potential of Valerian Constituents And Valerian Tinctures. Phytomedicine. 1998, 5(3): 219-225.
11. Bos R, Woerdenbag HJ, Vanputten FMS, et al. Seasonal Variation Of The Essential Oil, Valerenic Acid And Derivatives, And Valepotriates In Valeriana Officinalis Roots And Rhizomes, And The Selection Of Plants Suitable For Phytomedicines. Planta Medica. 1998, 64(2): 143-147.
12. Bos R. Isolation and identification of valerenane sesquiterpenoids from Valeriana officinalis. Phytochemistry, 1986, 25(1): 133-135.
13. Bos R. Woerdenbag HJ. Pras N. Determination of valepotriates. Journal of Chromatography. A. 2002, 967(1): 131-146.
14. Bounthanh C,, Bergmann C, Beck JP, et al. Valepotriates: a new class of cytotoxic and antitumor agents. Planta Med, 1981, 41(1): 21-28.
15. Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol. 1997, 11(2): 127-32.
16. Boyadzhiev, L, Kancheva, D, Gourdon, C, et al. Extraction of valerenic acids from valerian (Valeriana officinalis L.) rhizomes. Pharmazie. 2004, 59(9): 727-728.
17. Britta Schumacher, Silde scholle, Josef Holzl, et al. Lignans isolated from valerian: Identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J. Nat. Prod. 2002, 65: 1479-1485.
18. Buchbauer G, Jager W, Jirovetz L, Meyer F, Dietrich H. Effects of valerian root oil, bomeol, isoborneol, bornyl acetate and isobornyl acetate on the motility of laboratory animals(mice) after inhalationPharmazie. 1992, 47(8): 620-622.
19. Castillo P, Marquez J, Rubluo A, et al. Plant regeneration from callus and suspension cultures of Valeriana edulis ssp. procera via simultaneous organogenesis and somatic embryogenesis. Plant Sci. 2000, 151(2): 115-119.
20. Castillo P, Zamilpa A, Marquez J, et al. Comparative study of differentiation levels and valepotriate content of in vitro cultures and regenerated and wild plants of Valeriana edulis ssp. procera. J Nat Prod. 2002, 65(4): 573-575.
21. Cavadas C, Araujo I, Cotrim MD, et al. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung. 1995, 45(7): 753-755.
22. Chan TY. An assessment of the delayed effects associated with valerian overdose. Int J Clin Pharmacol Ther. 1998, 36(10): 569-572.
23. Dharmaratne H R, W. Nanayakkara N P D. Khan IA. (-)-3 beta, 4 beta-epoxyvalerenic acid from Valeriana officinalis. Planta Medica. 2002, 68(7): 661-662.
24. Diaper,-A, Hindmarch,-I .A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother-Res. 2004, 18(10): 831-836.
25. Dongsheng Ming, Jixian Guo. The structure of three sesquiter penoids from Valeriana jatamansi Jones. Tetrahedron letters, 1997, 38(29): 5205-5207.
26. Dorn M. Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative studyForsch Komplementarmed Klass Naturheilkd. 2000, 7(2): 79-84.
27. Eadie, MJ. Could valerian have been the first anticonvulsant?.Epilepsia. 2004, 45(11): 1338-1343.
28. Fernandez, S, Wasowski, C, Paladini, AC, et al. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol-Biochem-Behav. 2004, 77(2): 399-404.
29. Foerster W, Becker H, Rodriguez E. HPLC analysis of valepotriates in the North American genera Plectritis and Valeriana. Planta Med. 1984, (1): 7-9.
30. Foerster Wolfram,, et al. Effects of Plant bioregulators on the production of iridoid derived terpenoids in Valeriana wallichii and Fedia cornucopiae cell suspension cultures. Plant-Med, 1989, 6: 610-612.
31. Funke ED, Friedrich H. Valepotriates in the aerial parts of some more valerianaceae species. Planta Med. 1975, 28(3): 215-224.
32. Fussel A, Wolf A, Brattstrom A. Effect of a fixed valerian-Hop extract combination (Ze 91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res. 2000, 5(9): 385-390.
33. Gao XQ, Bjork L. Valerenic acid derivatives and valepotriates among individuals, varieties and species of Valeriana. Fitoterapia. 2000, 71(1): 19-24.
34. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998, 280(18): 1566-1567.
35. Gerhard U, Linnenbrink N, Georghiadou C, Hobi V. Vigilance-decreasing effects of 2 plant-derived sedativesSchweiz Rundsch Med Prax. 1996, 85(15): 473-481.
36. Giedke H, Breyer-Pfaff U. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000, 33(6): 239-243.
37. Goppel,-M, Franz,-G Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification ofvalerenic acids and lignans. Pharmazie. 2004, 59(6): 446-452.
38. Granger RE, Campbell EL, Johnston GA. (+)- And (-)-borneol: efficacious positive modulators of GABA action at human recombinant alpha, beta, gamma-GABAA receptors. Biochem Pharmacol. 2005, 69(7): 1101-1111.
39. Gutierrez,-S, Ang-Lee,-M-K, et al. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol-Biochem-Behav. 2004, 78(1): 57-64.
40. Hadley S, Petty JJ. Valerian. Am Fam Physician. 2003 15, 67(8): 1755-1758.
41. Hans Becker. Valepotriate Production of Normol and Colchine-treated Cell suspension Cultures of Valeriana wallichii. Journal of Natural Products, 1985, 48(1): 17-21.
42. Hazelhoff B. Isolation and analytical aspects of valeriana compounds. Pharm Weekbl Sci Ed, 1979, 1(4): 956-958.
43. Hendrick H, Bos R A, llerma D P, et al. Pharmacological screening ofvalerenal and some other components of the essential oil of Valeriana officinalis. Plant Med, 1981, 42(1): 62-68.
44. Hikino H, Hikino Y, Kobinata H, et al. A study on the efficacy of oriental drugs 18: sedative properties of Valeriana roots. Shoyauku Zasshi, 1980, 34(1): 19-24.
45. Hikino H, Kato T, Takemoto T. Constituents of wild Japanese valerian roots. (4). Yakugaku Zasshi. 1975, 95(2): 243-245.
46. Hiller K, Zetler G. 1996. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.: behavioral and anticonvulsant properties. Phytother Res, 1997, 10(2): 145-151.
47. Inouye H. Absolute configuration of valerisidate and didrovaltrate. Tetrahydron, 1974, 30(15): 2317-2319.
48. J. D. Hooker, C. B., K. C. S. I. Flora of British India. Vol.Ⅲ, 1882: 211-214.
49. Kammerer E. Phytogenic sedatives-hypnotics—does a combination of valerian and hops have a value in the modem drug repertoire? Z Arztl Fortbild(Jena). 1993, 87(5): 401-406.
50. Koich Nishiya. Sesquiterpenoids and iridoid glycosides from Valeriana fauriei. Phytochemistry, 1992, 36(6): 1547-1549.
51. Leathwood PD, Chauffard F, Heck E, et al. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982, 17(1): 65-71.
52. Lefebvre,-T, Foster,-B-C, Drouin, -C-E, et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J-Pharm-Pharm-Sci. 2004, 7(2): 265-273.
53. Leonhart S. Pedneault K. Gosselin A. Angers P. Papadopoulos AP. Dorais M. Diversification of greenhouse crop production under supplemental lighting by the use of new cultures with high economic potential. Proceedings Of The Fourth International Ishs Symposium On Artificial Lightings. 2002, 580: 249-254.
54. Letchamo, -W, Ward, -W, Heard, -B, et al. Essentiai oil of Valeriana offlcinalis L. cultivars and their antimicrobial activity as influenced by harvesting time under commercial organic cultivation. J-Agric-Food-Chem. 2004, 52(12): 3915-3919.
55. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav. 1989, 32(4): 1065-1066.
56. Malva, JO, Santos, S, Macedo, T. Neuroprotective properties ofValeriana officinalis extracts. Neurotox-Res. 2004, 6(2): 131-140.
57. Marder M, Viola H, Wasowski C, et al. 6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacoi Biochem Behav. 2003, 75(3): 537-545.
58. Mccabe S. Complementary herbal and alternative drugs in clinical practice. Perspect Psychiatr Care. 2002, 38(3): 98-107.
59. Mikell JR. Ganzera M. Khan IA. Analysis of sesquiterpenes in Valeriana officinalis by capillary electrophoresis. Pharmazie. 2001, 56(12): 946-948.
60. Motoo Torl. Aguaiane type sesquiterpene,valeracetate from Valeriana officinalis. Phytochemistry, 1981, 41 (3): 977-979.
61. Muller CE, Schumacher B, Brattstrom A, et al. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci. 2002, 71(16): 1939-1949.
62. Murakami N, Ye Y, Kawanishi M, Aoki S, Kudo N, Yoshida M, Nakayama EE, Shioda T, Kobayashi M. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett. 2002, 12(20): 2807-2810.
63. Nedyalka V. Handjieva, et al. Chemical ionization mass spectrometry of valepotriates using isobutane as reactant gas. Planta medica, 1987, 198-201.
64. Nishiya K, Kimura T, Takeya K, Itokawa H. Sesquiterpenoids and iridoid glycosides from Valeriana fauriei. Phytochemistry. 1992, 31 (10): 3511-3514.
65. Nobutoshi Murakami, Ying Ye, Motoyuki Kawanishi, et al. new Rev-transport inhibitor with anti-Hiv activity from Valerianae radix. Bioorganic & Medicinal Chemistry Letters. 2002, 12(20): 2807-2810.
66. Oliva I, Gonzalez-Trujano ME, Arrieta J, et al. Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice. Phytother-Res. 2004, 18(4): 290-296.
67. Ortiz JG. Nieves-Natal J. Chavez E Effects of Valeriana officinalis extracts on [H-3]flunitrazepam binding, synaptosomal ~3H-GABA uptake, and hippocampal [H-3]GABA release. Neurochemical Research. 1999, 24(11): 1373-1378.
68. Oshima Y, Matsuoka S, Ohizumi Y. Antidepressant principles of Valeriana fauriei roots. Chem Pharm Bull (Tokyo). 1995, 43(1): 169-170.
69. Otto Wilhelm, Thorne. Flora von Deutschland Osterreich und der Schweiz, 1885, Gera, Germany
70. Paul C, Konig WA, Muhle H. Pacifigorgianes and tamariscene as constituents of Frullania tamarisci and Valeriana officinalis.Phytochemistry. 2001, 57(2): 307-313.
71. Piccinelli, AL, Arana, S, Caceres, A, et al. New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities. J-Nat-Prod. 2004, 67(7): 1135-1140.
72. Plusbner SL. Valerian: Valeriana officinalis. Am J Health Syst Pharm. 2000, 57(4): 328, 333, 335.
73. Poyares DR, Guilleminault C, Ohayon MM, et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?Prog Neuropsychopharmacol Bioi Psychiatry. 2002, 26(3): 539-545.
74. Raymundez MB, Mathez J, Xena de Enrech N, et al. Coding of insertion-deletion events of the chloroplastic intergene atp beta-rbcL for the phylogeny of the Valerianeae tribe (Valerianaceae). C R Biol. 2002, 325(2): 131-139.
75. Rostovtseva T S. Chromosome numbers of some plant species from the south of Siberia Ⅱ. Bot. Zurn. SSSR, 1977, 62(7): 1034-1042.
76. S Kumar, K Tamura, and M Nei (2004) MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Briefings in Bioinformaties 5: 150-163.
77. Santos MS, Ferreira F, Cunha AP, et al. Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier. Arch Int Pharmacodyn Ther. 1994, 327(2): 220-231.
78. Santos MS, Ferreira F, Faro C, et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [~3H]GABA release in synaptosomes. Planta Med. 1994, 60(5): 475-476.
79. Schellenberg, R, Sauer, S, Abourashed, EA, et al. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta-Med. 2004, 70(7): 594-597.
80. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. 1994, 27(4): 147-151.
81. Schulz V. Rational Phytotherapy: A Physicians'Guide to Herbal Medicine(3rd Edition) Springer-Verlag Berlin Heidelberg Berlin in Germany. 1998.
82. Schumacher B, Scholle S, Hoizl J, Khudeir N, Hess S, Muller CE. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod. 2002, 65(10): 1479-1485.
83. Shohet D, Wills RB, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie. 2001, 56(11): 860-863.
84. Silva AL, Rech SB, yon Poser GL. Quantitative determination of valepotriates from Valeriana native to South Brazil. Planta Med. 2002, 68(6): 570-572.
85. Soltis, D. E., Senters, A. E., Zanis, M. J., et al. Gunnerales are sister to other core eudicots: implications for the evolution ofpentamery. Am. J. Bot. 2003, 90(3), 461-470.
86. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altem Med Rev. 2002, 7(2): 130-137.
87. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med.. 2000, 1(2): 91-99.
88. Suomi J, Wiedmer SK, Jussila M, et al. Analysis of eleven iridoid glycosides by micellar electrokinetic capillary chromatography (MECC) and screening of plant samples by partial filling (MECC)-electrospray ionisation mass spectrometry. J Chromatogr A. 2002, 970(1-2): 287-296.
89. Suomi J, Wiedmer SK, Jussila M, et al. Determination of iridoid glycosides by micellar electrokinetic capillary chromatography-mass spectrometry with use of the partial filling technique. Electrophoresis. 2001, 22(12): 2580-2587.
90. Takaiwa F, Oono K, Sugiura M. Nucleotide Sequence of the 17S-25S spacer region from rice rDNA. Plant Moleclar Biology, 1985, 4: 355-360.
91. Tang YP, Liu X, Yu B.. Two new flavone glycosides from Valeriana jatamansi. J Asian Nat Prod Res. 2003; 5(4): 257-261.
92. Thies PW. Die Konstitution der valepotriate mitteilung uber die Wirkstoffe des Baldrians. Tetrahedron, 1968, 24(1): 313-315.
93. Tittel G, Wagner H. High-performance liquid chromatographic separation and quantitative determination of valepotriates in valeriana drugs and preparations.J Chromatogr. 1978, 148(2): 459-68.
94.TohhoB B.A.缬草酊中缬草酸的发光指示剂容量分析法医学文摘,第三分册,药学:1965,8(1-2):127
95. Tortarolo M. Braun R, Hubner G E, et al. in vitro effects of epoxide-bearing valepotriates on mouse early hematopoietec progenitor cells and human T-lymphocytes. Arch Toxicol, 1982, 51(1): 37-41.
96. Trapskin,-P, Smith,-K-M. Herbal medications in the perioperative orthopedic surgery patient. Orthopedics. 2004, 27(8): 819-22.
97. Trevena, -L. Sleepless in Sydney—is valerian an effective alternative to benzodiazepines in the treatment of insomnia? ACP-J-Club. 2004, 141(1): 14-16.
98. Tufik S, Fujita K, Seabra Mde L, Lobo LL. Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring.J Ethnopharmacol. 1994, 41 (1-2): 39-44.
99. Uan,-C-S, Mehendale,-S, Xiao,-Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth-Analg. 2004, 98(2): 353-358.
100. Upton R. Valeriana officinalis. J Aitern Complement Med. 2001, 7(1): 15-17.
101. Veith J, Schneider G, Lemmer B, et al. The effect of degradation products of valepotriates on the motor activity of light-dark synchronized mice. Planta Med. 1986,(3): 179-183.
102. Vonderheid-Guth B, Todorova A, Brattstrom A, Dimpfel W. Pharmacodynamic effects of valerian and hops extract combination (Ze 91019) on the quantitative-topographical EEG in healthy volunteers. Eur J Med Res. 2000, 5(4): 139-144.
103. Wagner H, Jurcic K, Schaette R. Comparative studies on the sedative action of Valeriana extracts, valepotriates and their degradation products. Planta Med. 1980, 39(4): 358-365.
104. Wagner H, Schaette R, Horhammer L, Holzl J. Dependence of the valepotriate and essential oil content in Valeriana officinalis L.s.l. on various exogenous and endogenous factors. Arzneimittelforschung. 1972, 22(7): 1204-1209.
105. Wagner H, Chart V M.~(13)CNMR-stektren naturlich vorkommender flavonoide. Tetrahedron Lett, 1976, (21): 1799-1802.
106. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998, 32(6): 680-691.
107. Wasowski C, Marder M, Viola H, Medina JH, Paladini AC. Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichii. Planta Med. 2002, 68(10): 934-936.
108. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia.Phytother Res. 2001, 15(6): 549-551.
109. White T J, Bruns T, Lee S, et al. Amplification and Direct Sequencing of Fungal Ribosomal RNA Genes for Phylogenetics. California: Academic Press, 1990. 315-321.
110. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol. 1995, 37(4): 364-365.
111. Wohlfart R. Radix valerianae. History of an old medical drug, its active substances and their importance in the modern therapy. Z Allgemeinmed. 1974, 50(17): 797-800.
112. Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. 2004, 98(2): 353-358.
113. Yuping Tang, Xin Liu, Biao Yu. Iridoids from the Rhizomes and roots of Valeriana jatamansi. J. Nat. Prod. 2002, 65: 1949-1952.
114. Zhang, W. H., Chen, Z. D., Li, J. H., et al. Phylogeny of the Dipsacales s.1. based on chloroplast trnL-F and ndhF sequences. Jo Mol. Phylogenet. Evol. 2003, 26(2), 176-189.
115. Ziegler G. Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia—a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002, 7(11): 480-486.
116.丁小余,王峥涛,徐珞珊,等.F型、H型居群的铁皮石斛rDNAITS区序列差异及SNP现象的研究.中国中药杂志,2002,27(2):85-89.
117.于宝章,王遂义主编,河南植物志,河南科学技术出版社,1997:531-533.
118.卫生部药品生物制品研究所编.中国民族药志,第1卷.北京:人民卫生出版社,1977:633.
119.中国药典.1977年版,一部,北京:人民卫生出版社,1978:633.
120.中国药典.2005年版,一部,北京:人民卫生出版社,2005:附录XD.
121.中国科学院中国植物志编辑委员会.中国植物志.第73卷第1分册,北京:科学出版社,1986:27.
122.中国科学院昆明植物研究所.云南种子植物名录.云南人民出版社,1984:2012.
123.中国科学院昆明植物研究所编著.云南植物志.11卷.科学出版社,2000:533-538.
124.中国科学院植物研究所编.中国高等植物图鉴(第四册),科学出版社,1994:330-334.
125.中国药材公司.中国中药资源志要.科学出版社,1994:1217-1221.
126.云南省植物研究所编.云南经济植物,云南人民出版社,1973:316-317.
127.内蒙古植物志编辑委员会编.内蒙古植物志,第五卷,呼和浩特:内蒙古人民出版社,1980:359-360.
128.尹虹,薛存宽,叶建明,筹.缬草提取物抗心肌缺血再灌注损伤的实验研究.微循环学杂志 2000,10(1):12-14.
129.王云甫,严洁,孙圣刚,等.宽叶缬草对大鼠局灶性脑缺血后C-Fos、C-Jun表达的影响.广西医科大学学报.2004,21(1):10-12.
130.王云甫,严洁,罗国君,等.宽叶缬草治疗局灶性脑缺血的实验研究.中国康复.2004,19(3):137-138.
131.王冰,郑太坤,逯春玲,等.三种缬草形态组织特征鉴别.中药材,1998,21(4):177-179.
132.王杏林.用新HPLC法分析缬草提取物中缬草烯酸国外医药.植物药分册,1996,11(6):274-275.
133.王良信.缬草用于变态反应病、经度辐射后遗症的治疗及其抗疲劳作用.国外医学·中医中药分册.1995,17(6):29-30.
134.王建波,张文驹,陈家宽.核rDNA的ITS序列在被子植物系统与进化研究中的应用.植物分类学报.1999,37(4):407-416.
135.王菊英,董德慧.湖南缬草镇静作用的实验研究.实用医药杂志,1996,9(2):17-18.
136.兰茂著.《滇南本草》整理组整理.滇南本草.第2卷.昆明:云南人民出版社,1977:273
137.叶建明,薛存宽,尹虹,等.缬草提取物对类脂质代谢的影响与对胆囊结石治疗作用的关系. 临床消化病杂志,2002,14(1):25-27.
138.司晓芸,贾汝汉,黄从新,等.宽叶缬草对高胆固醇血症大鼠肾组织内7G-β1表达的影响 中国中药杂志.2003,28(9):845-848.
139.石晋丽,刘勇,肖培根.等.长序缬草的形态组织鉴定中药材.2003,26(8):554-556.
140.任世兰.于龙顺,裴宁,等.宽叶缬草对平滑肌和心血管的药理研究.中草药,1982,13(3):23-26.
141.刘慎谔主编.东北药用植物志.科学出版社,1959:183.
142.朱有昌.东北产缬草属药用植物.药学学报,1955,3(11):516-518.
143.朱有昌主编.东北药用植物.哈尔滨:黑龙江科学技术出版社,1989:1073-1076.
144.朱亮锋,陆碧瑶,李毓敬,贾良智.芳香植物及其化学成分.海南人民出版社,1988:100.
145.江苏省植物研究所编.江苏植物志(下册).江苏科学技术出版社,1982:801-802.
146.江泽荣,余亚刚,米景森.毛节缬草的生药学研究.药学学报,1964,11(11):778-786.
147.吴华欣.缬草属植物化学成分及药理作用研究的回顾.云南中医杂志,1985,6(1):49-51.
148.吴征镒,路安民,汤彦承,陈之端,李德铢著.中国被子植物科属综论.北京:科学出版社,2003:867-870.
149.吴征镒主编.西藏植物志.第四卷.北京:科学出版社,1985:514-518.
150.吴征镒主编.新华本草纲要.第二册.上海:上海科学技术出版社,1991:498-500.
151.吴家荣.中草药蜘蛛香(印度缬草)的鉴定研究.新医药通讯.1976,(1):73-78
152.宋.高承.事物纪原.卷十.丛书集成,商务印书馆,1937:1212.
153.宋金枝,杨树春,郭宝英.缬草的开发及栽培技术.特种经济动植物.2002,5(3):34-34.
154.张人伟,吴华欣,李勤华,等.马蹄香环烯醚萜类成分的分离鉴定.云南植物研究,1986,8(1):107-109.
155.张宏达,黄云晖,缪汝槐,叶创兴,廖文华,金建华著.种子植物系统学.北京:科学出版社,2004:409-410.
156.张振学,姚新生.药用植物缬草的化学研究进展.中国药物化学杂志,2000,10(3):226-230.
157.张振学,姚新生.药用植物缬草的生物活性研究进展与开发.沈阳药科大学学报,2000,17(3):222-225.
158.张素霞.缬草根和根茎中的挥发油、缬草酸及其衍生物和缬草三酯含量的季节变化及药用植株选择.国外医药.植物药分册,1999,14(1):21-22.
159.李书心主编.辽宁植物志(下).辽宁科学技术出版社,1992:400-405.
160.李世全主编.秦岭巴山天然药物志.西安:陕西科学技术出版社,1987:19,227.
161.李时珍.《本草纲目》(校对本).第2册,北京:人民卫生出版社,1979:845.
162.李宗友.阔叶缬草的抗抑郁成分.国外医学.中医中药分册,1996,18(2):47-48.
163.李恒,郭辉军,刀志灵主编.高黎贡山植物.科学出版社,2000:897-898.
164.杜怡斌主编.河北野生植物资源植物志.保定:河北大学出版社,2000:244-245.
165.杨春荣,单静颖,刘莉,等.毛节缬草的解剖构造观察黑龙江医药科学.2003,26(6):25-26.
166.杨桂元,王玮.宽叶缬草治疗冠心病的临床研究.中国中西医结合杂志.1994,14(9):540-542.
167.杨桂元,徐青,王俊峰.宽叶缬草对动脉平滑肌细胞收缩及生长的影响.郧阳医学院学报.2002,21(6):324-326.
168.杨晶,薛存宽,朱咸中.~(86)Rb摄取示踪法评定几种中草药提取物对心、肾组织微循环灌流量的影响.微循环学杂志,1998,8(1):15-17.
169.谷力,谷臣华.武陵山区缬草属种类和优良种及其化学成分的研究.林产化学与工业,2002,22(3):23-27.
170.谷臣华,张永康,谷力,等.野生和人工栽培窄裂缬草香精油的GC/MS分析对比研究.吉首大学学自然科学版,1998,19(3):53-56.
171.谷臣华.谷忠村,张永康.缬草属香料植物种类与人工驯化栽培研究.吉首大学学报:自然科学版,1998,19(2):20-23.
172.迟港民主编.山东植物志(下).青岛出版社,1997:1224-1227.
173.邱莲卿.西藏缬草属一新种,植物分类学报,1979,17(3):124.
174.邱莲卿.缬草属新分类群.云南植物研究,1986,8(1):45-47.
175.陆顺芳.过量服用缬草的安全性得到证实.中草药,1996,27(11):698.
176.陈训,巫华美,刘朝辉,等.贵州两种一变种缬草属植物染色体研究.云南植物研究1997,19(4):449-450.
177.陈虎彪,朱建民,赵玉英,等.药用缬草及其中国产近缘种的化学分类学研究.中成药1999.21(12):652-654.
178.陈虎彪,诚静容.国产败酱科药用植物种类整理.中国中药杂志,1994,19(2):67-71.
179.陈虎彪,诚静容.中国欧缬草近缘种的分类订正.植物研究,1991,11(3):29-40.
180.陈虎彪,诚静容.西南缬草属一新种.广西植物.1992,12(2):97-98.
181.陈虎彪.缬草属一些存疑种的考订.植物研究.1994.14(1):37-39.
182.陈柏华,李晓华,张群林.宽叶缬草对兔动脉损伤后内膜增生的抑制作用研究.数理医药学杂志.2004,17(4):316-318.
183.陈玲,贾汝汉,丁国华,等.缬草油对2型糖尿病大鼠肾脏的保护作用及其机制探讨中华肾脏病杂志.2003,19(3):168-172.
184.陈科力,谭文界.缬草的生药鉴定.中药材,1993,16(6):17-19.
185.陈家宽.中国慈姑属的系统与进化植物学研究.武汉大学出版社,1989:90-100.
186.陈磊,秦路平,郑汉臣,等.三种缬草属植物的缬草素类含量种间和种内比较.中药材 2002,25(4):237-238.
187.陈磊,秦路平,郑汉臣.缬草的化学成分、植物资源和药理活性.药学实践杂志.2000,18(5):277-279.
188.陈磊,康鲁平,秦路平,等.总缬草素的质量标准和镇静催眠活性研究.中成药.2003,25(8):663-665.
189.陈磊,康鲁平,秦路平,等.缬草属药用植物HPLC指纹特征研究.中药材.2003,26(4):256-259.
190.陈冀胜,郑硕主编.中国有毒植物,科学出版社,1987:609-610.
191.周以良等编著.中国大兴安岭植被,科学出版社,1991:235-235.
192.周琳,张悦,张静,等.缬草开发前景广阔.国土与自然资源研究.2003(3):91-92.
193.屈文,杨静,鼓仁,等.缬草复方制剂对大鼠脑缺血的保护作用.中国药理通讯.2003,20(1):53-55.
194.巫华美,刘朝辉.陈训.缬草属两种一变种过氧化物酶同工酶研究.贵州科学,1996,14(4):26-28.
195.明东升,郭济贤,顺庆生等.中药蜘蛛香和缬草类的形态组织学研究.上海医科大学学报,1993.20(3):205-207.
196.明东升,郭济贤,顺庆生,等.四种缬草生药挥发油化学成分的气相层析:质谱联用鉴定.中成药.1994,16(1):41-42.
197.明东升,郭济贤.缬草类生药中总缬草素的含量测定.上海医科大学学报.1993,20(3):210-212.
198.林杰,郑宏钧.蜘蛛香的形态组织鉴定.中药材,1995,18(8):387-389.
199.罗士德编著.中草药抗艾滋病病毒活性研究,云南科技出版社,1998:130.
200.罗国君,席刚明,范华燕.等.宽叶缬草对兔蛛网膜下腔出血后基底动脉管径和血流速度的影响.中国中医药科技,2001,8(5):310-311.
201.罗国君,席刚明,范华燕,等.宽叶缬草治疗兔蛛网膜下腔出血后脑血管痉挛的实验研究.江苏中医药,2002,23(5):39-41.
202.范志强,张治国.国内缬草属植物药理研究近况.中国新药杂志,1998,7(S:S):15-17.
203.郄建坤,屈会化,等.缬草属植物化学成分及药理研究概况.中国药学杂志,2002,37(10):729-733.
204.郑汉臣主编.药用植物学.第三版,北京:人民卫生出版社,1999:260.
205.郑重编.湖北植物大全.武昌:武汉大学出版社,1993:412-413.
206.侯宽昭.中国种子植物科属词典(修订版).北京:科学出版社,1982:510-511.
207.南京药学院《中草药学》编写组.中草药学.下册.南京:江苏人民出版社,1980:1085.
208.洪德元.缬草属(败酱科)的两个新种.植物分类学报,1992,30(4):371-374.
209.祝廷成,严仲铠,周守标主编.中国长白山植物.北京科学技术出版社,延吉市:延边人民出版社,2003:396-398.
210.美国药典(24版):缬草(Valerian)国外医药.植物药分册,2002,17(3):126-127.
211.胡昌兴,杨桂元,李庚山.宽叶缬草对实验性高脂血症家兔血脂代谢的影响.郧阳医学院学报,1998,17(3):131-133.
212.赵小兰,姚崇怀.桂花花粉形态种内变异的研究.湖北民族学院学报(自然科学版).1999,17(1):16-20.
213.钟扬,陈家宽,黄德世编著.数量分类的方法与程序.武汉大学出版社,1990:195-290.
214.钟扬,陈家宽.矮慈菇居群的数量分类研究.广西植物,1991,11(4):304-307.
215.徐红,袁惠南,潘丽华,等.缬草挥发油对中枢神经系统药理作用的研究.药物分析杂志 1997.17(6):399-401.